

1). Interestingly, there was a prompt decrease of fasting blood glucose (mean  $4.86 \pm 0.41$  mmol/l,  $P > 0.001$  by repeated-measures ANOVA) after 3 months of readministration of infliximab. Infliximab has been administered in 8-week intervals, and until present, the patient has had stable fasting blood glucose in the nondiabetic range.

Our case strongly supports the hypothesis that chronic TNF- $\alpha$  blockade impacts glucose metabolism. First, the patient's diabetes disappeared during the chronic administration of infliximab due to active psoriatic arthritis, and then he redeveloped diabetes at the infliximab-free interval. After the readministration of the anti-TNF- $\alpha$  antibody, fasting blood glucose was normalized again.

Further prospective studies are strongly needed to investigate the effects of an anti-TNF- $\alpha$  antibody on insulin sensitivity and  $\beta$ -cell function in insulin resistant or diabetic patients.

BABAK YAZDANI-BIUKI, MD<sup>1</sup>  
 THOMAS MUELLER, MD<sup>1</sup>  
 HANS-PETER BREZINSCHKEK, MD<sup>1</sup>  
 JOSEF HERMANN, MD<sup>1</sup>  
 WINFRIED GRANINGER, MD<sup>1</sup>  
 THOMAS C. WASCHER, MD<sup>2</sup>

From the <sup>1</sup>Department of Internal Medicine, Division of Rheumatology, Medical University Graz, Styria, Austria; and the <sup>2</sup>Department of Internal Medicine, Metabolism and Vascular Biology Unit, Medical University Graz, Styria, Austria.

Address correspondence to Dr. Babak Yazdani-Biuki, Medizinische Universitätsklinik, Auenbruggerplatz 15, A-8036 Graz, Austria. E-mail: babak.yazdaniubiuki@meduni-graz.at.

DOI: 10.2337/dc06-0636

© 2006 by the American Diabetes Association.

References

1. Greenberg AS, McDaniel ML: Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. *Eur J Clin Invest* 32 (Suppl. 3):24–34, 2002
2. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T: Tumor necrosis factor- $\alpha$  in sera of obese patients: fall with weight loss. *J Clin Endocrinol Metab* 83:2907–2910, 1998
3. Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippel P, Graninger W, Wascher TC: Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF- $\alpha$  antibody infliximab (Letter). *Eur J Clin Invest* 34:641–642, 2004
4. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA: Effects of infliximab

treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. *Ann Rheum Dis* 64:765–766, 2005

**Gestational Diabetes Mellitus in Sardinia**

Results from an early, universal screening procedure

The prevalence of gestational diabetes mellitus (GDM) ranges from 1 to 14% of all pregnancies, depending on the population studied and the diagnostic test and its glycemic cutoff, and it mirrors the prevalence of type 2 diabetes (1). The prevalence of GDM in Italy was reported to be 2.3–10% (2).

Sardinia has, with Finland, the highest prevalence in the world of type 1 diabetes and type 1 diabetes-related autoimmune disease (3), while the prevalence of type 2 diabetes is similar to that of other, not high-risk, populations. Its prevalence of GDM is still unknown.

Aiming to verify the prevalence of GDM in a large group of Sardinian women, we studied 1,103 pregnant volunteers of mean age  $31 \pm 5$  years (range 16–46) and BMI  $22.5 \pm 3.8$  kg/m<sup>2</sup> (12.7–47.2) who gave consent to take part in an extended, universal screening procedure, at 16–18, 24–26, and 30–32 weeks of gestations. This protocol was chosen, together with a low glycemic threshold (130 mg/dl) for the oral glucose tolerance test, to avoid undiagnosed cases of GDM. Oral glucose tolerance test and diagnosis of GDM were performed according to the American Diabetes Association (4).

We showed a very high (247/1,103; 22.3%) prevalence of GDM, of which 28.4% was diagnosed at 16–18 weeks (prevalence 6.6%), 25.9% at 24–26 weeks (5.8%; not significant vs. 16–18 weeks), and 44.5% at 30–32 weeks (9.9%;  $P < 0.01$  vs. 20–24 weeks and  $P < 0.02$  vs. 16–18 weeks). The 130-mg/dl threshold allowed us to detect 12.8% more GDM cases compared with the 140 mg/dl threshold. The difference in prevalence of GDM between our group and others, particularly other Italian regions, is only partially explainable by our extended screening procedure. Furthermore, it is in contrast with the prevalence of type 2 diabetes in Sardinia. Consider-

ing the genetic and immunological characteristics of the Sardinian population, we postulate that a greater proportion of our GDM cases than that reported by others (5) can have autoimmune origin and thus be associated with the high type 1 prevalence in our island. This hypothesis is strengthened by the low prevalence of obesity (4.9%) and the relatively low BMI of our patients. An autoantibody panel is currently under investigation in our laboratory.

CINZIA MURGIA, MD<sup>1</sup>  
 RACHELE BERRIA, MD<sup>2</sup>  
 LUIGI MINERBA, MD<sup>3</sup>  
 BARBARA MALLOCI, MD<sup>1</sup>  
 CLAUDIA DANIELE, MD<sup>1</sup>  
 PIERINA ZEDDA, RN<sup>1</sup>  
 M. GIOVANNA CICCOTTO, MD<sup>1</sup>  
 SIMONETTA SULIS, MD<sup>1</sup>  
 MICHELA MURENU, MD<sup>1</sup>  
 FRANCO TIDDIA, MD<sup>4</sup>  
 MARIO MANAI, MD<sup>5</sup>  
 GIAN BENEDETTO MELIS, MD<sup>1</sup>

From the <sup>1</sup>Clinica Ostetrica e Ginecologica, Università degli Studi di Cagliari, Ospedale San Giovanni di Dio, Cagliari, Italy; the <sup>2</sup>Department of Obstetrics and Gynecology, Case Western Reserve University, Cleveland, Ohio; the <sup>3</sup>Dipartimento di Sanità Pubblica, Università degli Studi di Cagliari, Italy; the <sup>4</sup>Laboratorio Analisi Chimico Cliniche e Microbiologia, Ospedale San Giovanni di Dio, Cagliari, Italy; and the <sup>5</sup>Servizio di Diabetologia, Ospedale San Giovanni di Dio, Cagliari, Italy.

Address correspondence to Cinzia Murgia, MD, Clinica Ostetrica e Ginecologica, Università degli Studi di Cagliari, Ospedale San Giovanni di Dio, Via Ospedale 46, Cagliari, Italy 09100. E-mail: cinziamurgia@tiscali.it.

DOI: 10.2337/dc06-0635

© 2006 by the American Diabetes Association.

References

1. King H: Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. *Diabetes Care* 21 (Suppl. 2):B9–B13, 1998
2. Di Cianni G, Volpe L, Lencioni C, Miccoli R, Cuccuru I, Ghio A, Chatzianagnostou K, Bottone P, Teti G, Del Prato S, Benzi L: Prevalence and risk factors for gestational diabetes assessed by universal screening. *Diabetes Res Clin Pract* 62:131–137, 2003
3. Songini M, Muntoni S: High incidence of type 1 diabetes in Sardinia. *Lancet* 337: 1047, 1991
4. American Diabetes Association: Gestational diabetes mellitus (Position Statement). *Diabetes Care* 26 (Suppl. 1):S103–S105, 2003
5. Weng J, Ekelund M, Lehto M, Li H, Ekberg G, Frid A, Aberg A, Group LC, Bertorp K: Screening for MODY mutations, GAD antibodies and type 1 diabetes asso-

ciated HLA genotypes in women with gestational diabetes mellitus. *Diabetes Care* 25:68–71, 2002

## Areca Nut Chewing Is Associated With Metabolic Syndrome

Role of tumor necrosis factor- $\alpha$ , leptin, and white blood cell count in betel nut chewing-related metabolic derangements

**A**reca nut (*Areca catechu*)/betel quid (BQ) is said to be the fourth most commonly used psychoactive substance in the world and is chewed regularly by at least 10% of the world's population (1). High prevalences of BQ chewing were observed especially in South and Southeast Asia (1). High prevalences of insulin resistance and metabolic syndrome were also observed in this area (2). Specific areca alkaloids act as competitive inhibitors of  $\gamma$ -aminobutyric acid receptors in the brain, cardiovascular system, and pancreas, which may promote one's appetite or altered insulin secretion (3). Moreover, BQ components have recently been shown to induce keratinocytes to secrete tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-6, as well as induce reactive oxygen species and activate nuclear factor- $\kappa$ B expression (4), which may potentially provoke chronic inflammation. Recently, we confirmed that BQ chewing was associated with a higher risk of type 2 diabetes and central obesity in Taiwanese men (5). The detrimental effects of BQ chewing on selected components of the metabolic syndrome, and the induction of inflammatory cytokines and factors, raise the possibility that BQ chewing may increase the risk of metabolic syndrome.

In this study, a total of 1,466 aboriginal subjects of Southern Taiwan, 30–95 years of age, were enrolled. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III definition. The age-adjusted prevalence of metabolic syndrome in the aborigines studied was 41.1% in men and 42.4% in women. BQ-chewing subjects had significantly higher prevalences of central obesity, hypertriglyceridemia, dysglycemia, and metabolic syndrome than those of nonchewers. Peripheral leukocyte count also significantly

increased in chewers of both sexes, with plasma TNF- $\alpha$  level increased in men and plasma leptin level elevated in women. All were parallel to the number of components of the metabolic syndrome. Multiple logistic regression modeling adjusted for age, educational level, socioeconomic level, exercise, drinking, and smoking status showed that BQ chewing is an independent risk factor for the metabolic syndrome. The adjusted OR (95% CI) for male BQ chewers was 1.92 (1.15–3.27) and that of female chewers was 1.60 (1.03–2.50). The study shows that chronic BQ chewing is an independent contributor of metabolic syndrome. TNF- $\alpha$ , leptin, and leukocyte count are involved in BQ chewing-related metabolic derangements.

FU-MEI CHUNG, MS<sup>1,2</sup>  
 DAO-MING CHANG, MD<sup>1,5</sup>  
 MIAO-PEI CHEN, MS<sup>1</sup>  
 JACK C.-R. TSAI, MD, MPH<sup>1,3</sup>  
 YI-HSIN YANG, PHD<sup>4</sup>  
 TIEN-YU SHIEH, PHD<sup>4</sup>  
 SHYI-JANG SHIN, MD, PHD<sup>3</sup>  
 TONY HSIU-HSI CHEN, PHD<sup>5</sup>  
 TONG-YUAN TAI, MD, PHD<sup>6</sup>  
 YAU-JIUNN LEE, MD, PHD<sup>1</sup>

From the <sup>1</sup>Department of Clinical Research, Pingtung Christian Hospital, Pingtung, Taiwan; the <sup>2</sup>Graduate Institute of Dental Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan; the <sup>3</sup>Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; the <sup>4</sup>Graduate Institute of Oral Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan; the <sup>5</sup>Institute of Preventive Medicine and Public Health, National Taiwan University, Taipei, Taiwan; and the <sup>6</sup>Department of Internal Medicine, Ren-Ji Hospital, Taipei, Taiwan.

Address correspondence to Dr. Yau-Jiunn Lee, Department of Clinical Research, Pingtung Christian Hospital, No. 60 Da-Lien Rd., Pingtung, 90000, Taiwan. E-mail: t3275@ms25.hinet.net.

DOI: 10.2337/dc06-0628

© 2006 by the American Diabetes Association.



### References

- Gupta PC, Ray CS: Epidemiology of betel quid usage. *Ann Acad Med Singapore* 33: 31–36, 2004
- Abate N, Chandalia M: Ethnicity and type 2 diabetes: focus on Asian Indians. *J Diabetes Complications* 15:320–327, 2001
- Johnston GA, Krogsgaard-Larsen P, Stephanson A: Betel nut constituents as inhibitors of gamma-aminobutyric acid uptake. *Nature* 258:627–628, 1975
- Lin SC, Lu SY, Lee SY, Lin CY, Chen CH, Chang KW: Areca (betel) nut extract activates mitogen-activated protein kinases and NF- $\kappa$ B in oral keratinocytes. *Int J Cancer* 116:526–535, 2005

- Tung TH, Chiu YH, Chen LS, Wu HM, Boucher BJ, Chen TH: A population-based study of the association between areca nut chewing and type 2 diabetes mellitus in men (Keelung Community-based Integrated Screening programme No. 2). *Diabetologia* 47:1776–1781, 2004

## An Epidemiologic Study on the Prevalence of Diabetes, Glucose Intolerance, and Metabolic Syndrome in the Adult Population of the Republic of Cyprus

**T**he study was conducted in Cyprus (November 2003 through January 2005). Stratified random sampling was used to select 1,200 individuals aged 20–80 years (from a total population of 477,000). In all subjects, anthropometrical measurements were taken, fasting lipids were measured, eating habits were evaluated according to a standardized questionnaire, and an oral glucose tolerance test (OGTT) was performed (except in known diabetic patients).

In the absence of OGTT-diagnosed diabetes or impaired glucose tolerance (IGT), impaired fasting glucose (IFG) was defined by fasting plasma glucose  $\geq 110$  mg/dl and  $< 126$  mg/dl, whereas “new” IFG was defined by fasting plasma glucose  $\geq 100$  and  $< 126$  mg/dl. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria.

Of the 1,200 subjects, 78 (6.5%) had known diabetes and 45 (3.8%) were newly diagnosed by the OGTT, which brought the total prevalence of diabetes to 123 (10.3%). Another 78 (6.5%) subjects had IGT, 36 (3.0%) had IFG, and 171 (14.2%) had “new” IFG. Logistic regression showed that significant risk factors for diabetes were age, male sex, family history of diabetes ( $P < 0.001$ ), hypertension ( $P = 0.004$ ), and obesity ( $P = 0.003$ ). Risk factors for IGT were age and family history of diabetes ( $P < 0.01$ ). Risk factors for IFG and “new” IFG were age and obesity ( $P < 0.01$ ).

The prevalence of metabolic syndrome was 22.2% overall, 68.5% among subjects with diabetes, 43.6% among